Livzon Pharmaceutical Group Inc (000513)

Currency in CNY
42.47
+3.86(+10.00%)
Closed·
000513 Scorecard
Full Analysis
Management has been aggressively buying back shares
Unusual trading volume
Fair Value
Day's Range
38.6342.47
52 wk Range
32.9444.72
Key Statistics
Bid/Ask
42.47 / 42.47
Prev. Close
38.61
Open
38.63
Day's Range
38.63-42.47
52 wk Range
32.94-44.72
Volume
39.27M
Average Volume (3m)
8.4M
1-Year Change
11.67%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
000513 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
39.59
Downside
-6.79%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Livzon Pharmaceutical Group Inc Company Profile

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers Ilaprazole enteric-coated tablets and ilaprazole sodium for injection a series of bismuth potassium citrate products for gastrointestinal field; leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for assisted reproduction field; fluvoxamine maleate and perospirone hydrochloride tablets for psychiatric and neurological field; and shenqi fuzheng injection and anti-viral granules for traditional chinese medicine field. It also produces APIs and intermediates, such as mevastatin, acarbose, phenylalanine, vancomycin hydrochloride, daptomycin, milbemycin oxime, and ceftriaxone sodium; diagnostic reagents such as diagnostic kit for IgM antibody to mycoplasma pneumonia; diagnostic kit for human immunodeficiency virus antibody; and livzon antinuclear antibody test kit. In addition, the company offers nucleic acid test kits; livzon interferon-gamma release assays test kits; diagnostic kit for IgM antibody to mycoplasma pneumonia; influenza A/B virus antigen detection kit; and treponema pallidum antibody detection kit. Further, it provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics, as well as diagnostic reagents and equipment. Livzon Pharmaceutical Group Inc. was founded in 1985 and is headquartered in Zhuhai, China.

Employees
9067
Market
China

Compare 000513 to Peers and Sector

Metrics to compare
000513
Peers
Sector
Relationship
P/E Ratio
16.1x24.3x−0.5x
PEG Ratio
2.100.090.00
Price/Book
2.4x2.1x2.6x
Price / LTM Sales
2.9x2.1x3.2x
Upside (Analyst Target)
1.8%13.6%45.3%
Fair Value Upside
Unlock12.6%7.4%Unlock

Analyst Ratings

4 Buy
1 Hold
1 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 39.59
(-6.79% Downside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.29%
Dividend Yield
2.85%
Industry Median 1.57%
Annualised payout
1.10
Paid unevenly
5-Years Growth
-0.89%
Growth Streak

Earnings

Latest Release
Apr 23, 2025
EPS / Forecast
0.71 / 0.68
Revenue / Forecast
3.18B / 3.34B
EPS Revisions
Last 90 days

000513 Income Statement

FAQ

What Stock Exchange Does Livzon Pharm A Trade On?

Livzon Pharm A is listed and trades on the Shenzhen Stock Exchange stock exchange.

What Is the Stock Symbol for Livzon Pharm A?

The stock symbol for Livzon Pharm A is "000513."

What Is the Livzon Pharm A Market Cap?

As of today, Livzon Pharm A market cap is 30.16B.

What Is Livzon Pharm A's Earnings Per Share (TTM)?

The Livzon Pharm A EPS (TTM) is 2.29.

When Is the Next Livzon Pharm A Earnings Date?

Livzon Pharm A will release its next earnings report on 20 Aug 2025.

From a Technical Analysis Perspective, Is 000513 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Livzon Pharm A Stock Split?

Livzon Pharm A has split 6 times.

How Many Employees Does Livzon Pharm A Have?

Livzon Pharm A has 9067 employees.

What is the current trading status of Livzon Pharm A (000513)?

As of 16 Jul 2025, Livzon Pharm A (000513) is trading at a price of 42.47, with a previous close of 38.61. The stock has fluctuated within a day range of 38.63 to 42.47, while its 52-week range spans from 32.94 to 44.72.

What Is Livzon Pharm A (000513) Price Target According to Analysts?

The average 12-month price target for Livzon Pharm A is CNY39.586, with a high estimate of CNY44.8 and a low estimate of CNY28.88. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an -6.79% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.